Jump to content

Lung Cancer Vaccine


Recommended Posts

The Company also announced that median survival for patients with Stage IIIB locoregional non-small cell lung cancer who received BLP25 Liposome Vaccine (L-BLP25) in a phase 2b study has been determined [30.6 months compared with 13.3 months for the unvaccinated group].

Link to comment
Share on other sites

BLP25 has been taken over by Merck KgaA/EMD Pharmaceuticals under the name Stimuvax. Phase III Clinical Trial to start mid 2006. I strongly recommend anyone interested in more information or participating go the following link.


password: vaccine

just fill in the rest

***Once you get into the website click on "View L-BLP25 Animation" and watch the video***

Link to comment
Share on other sites

  • 3 weeks later...

Stimuvax® (formerly referred to as BLP25 Liposome Vaccine) – mimics the mucin MUC1, which is present on many tumors On January 26, 2006, Merck KGaA and its co-development partner Biomira Inc. announced the signing of a binding letter of intent to amend the licensing agreement for Stimuvax. The amended agreement gives Merck global development and marketing rights to the vaccine except in Canada, where the companies share rights to the vaccine. Under the letter of intent, Merck takes over full responsibility – both administrative and financial – for development and commercialization of Stimuvax, including the planned Phase III trial in NSCLC, which remains on track to start this summer. Survival results from the Phase IIB trial in Stage IIIB and IV non-small cell lung cancer (NSCLC) patients indicated a 4.4 month longer median survival for patients randomized to the Stimuvax arm (88 patients) compared to the best supportive care (BSC) arm (83 patients). The greatest benefit was observed in vaccinated patients with Stage IIIB locoregional NSCLC, which makes up approximately 25 percent of patients with this form of cancer. Median survival – reached for the vaccinated subset of Stage IIIb locoregional patients in October 2005 – was 30.6 months compared to 13.3 months observed for the same stage patients who did not receive the vaccine, a difference of 17.3 months. Though not statistically significant, the survival update provides additional clarity for statistical considerations for the planned Phase III trial.1,2

Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Reply to this topic...

×   Pasted as rich text.   Restore formatting

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

  • Create New...

Important Information

By using this site, you agree to our Terms of Use. We have placed cookies on your device to help make this website better. You can adjust your cookie settings, otherwise we'll assume you're okay to continue.